Vornorexant (C09-1184-933)

Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects? in vivo and can be used for insomnia research researchIn VivoVornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep . Vornorexant exhibits optimal PK properties with a rapid T max and short half-lives in rats and dogs. The T 1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat Dosage: 1, 3, 10 mg/kg Administration: Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg Result: Possessed promising sleep-inducing and sleep-promoting effects.Form:SolidIC50& Target:OX 2 Receptor. Specification: 0.99 Molecular Formula: C23H22FN7O2 Molecular Weight: 447.46 PubChem CID: 137419776 Isomeric SMILES: CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCO[C@H]3CN4C=CC(=N4)C5=NC=C(C=C5)F